OncoSec Medical Inc (ONCSQ)

[twiz0019]

So I went back and listened to yesterday's presentation and Punit DID indeed say that they are looking for a 30% response rate in the combo trial..he says that at about 20:40 on the audio. Since he already knows the data, I think it's safe to assume that we will see at least that 30% response rate. He also says that non-responders really have no other options once they fail Keytruda or any other checkpoint inhibitor as a monotherapy. Again, being able to turn non-responders into responders IS a big deal. You have to believe that Merck or any other drug company with a checkpoint inhibitor would love to have 30% more people respond to their drug. Combination therapy is where it's at in immunotherapy and ONCS is looking to be at the forefront when dealing with non-responders in melanoma and possibly other cancers as well.